Every article, presentation, spotlight, and news item we've tagged to Hallmarks of Aging.
Showing 121–144 of 239
In aged ovarian cancer, elevated succinate in the tumor microenvironment drives metabolic reprogramming of regulatory T cells, amplifying immunosuppression and reducing survival. Pharmacological inhibition of succinate metabolism restores effector T cell activity and improves outcomes, identifying a metabolic mechanism underlying age-related cancer progression.
Chromosomal passenger complex proteins show age-dependent dysregulation in the uterus during implantation and decidualization in aging female mice, with reduced cell proliferation markers and altered protein expression patterns that correlate with reduced implantation success. These findings identify a cellular mechanism underlying age-related fertility decline independent of ovarian function.
Vesalic's discovery identifies a systemic metabolic dysfunction marked by altered lipid composition in circulating extracellular vesicles in ALS patients' blood. This reframes neurodegenerative diseases as downstream consequences of upstream metabolic abnormalities rather than purely neurological conditions localized to the brain, with implications for earlier detection and intervention across multiple neurodegenerative pathologies.
Senescent cells drive postpartum mammary gland involution and tissue remodeling, but simultaneously create a microenvironment permissive to tumor initiation. This reveals how a tissue repair mechanism can paradoxically increase cancer risk during a critical metabolic transition.
Visceral adipose tissue accumulation in midlife correlates with metabolic dysfunction, but the relationship is contextual rather than categorical. The review identifies conditions under which visceral fat becomes pathogenic and describes interventions to mitigate harm.
Local radiation injury triggers a cascade in which damaged skin cells release eccDNA, activating immune signaling in the spleen that produces hyperactive neutrophils expressing high levels of galectin-9. These neutrophils infiltrate multiple organs, disrupt bone marrow function, and drive sustained immune dysregulation that accelerates frailty—a finding that identifies a specific mechanistic pathway underlying radiation-induced aging and functional decline.
Lysoway Therapeutics has initiated Phase 1 testing of LW-1017, a small-molecule TRPML1 agonist designed to restore autophagy-lysosomal function in neurodegenerative diseases including Alzheimer's and Parkinson's. The compound represents a potential intervention targeting cellular waste clearance mechanisms that decline with age.
Sepsis triggers distinct molecular responses based on age and sex, with older adults and females showing different patterns of gene expression and immune activation. These findings establish that one-size-fits-all sepsis treatment protocols may be biologically misaligned with how different populations actually respond to systemic infection.
ACSS2, an enzyme that metabolizes acetate, is required to maintain oligodendrocyte progenitor cells and sustain myelination across the lifespan. Impaired acetate utilization during aging contributes to declining myelin formation, a hallmark of neurological aging.
Cellular senescence—the accumulation of cells that cease dividing but resist death—has emerged as a primary target in longevity medicine due to evidence that clearing these cells extends healthspan and can address root causes of age-related disease. Senotherapeutics, including senolytics and senomorphics, are transitioning from preclinical studies to clinical trials, though significant challenges in biomarker standardization, cellular heterogeneity, and clinical efficacy remain.
Dietary restriction demonstrates geroprotective effects across species through multiple molecular pathways, though human data remains inconsistent and mechanistic understanding incomplete. This class of intervention represents a critical reference point for evaluating longevity strategies, particularly in identifying which downstream mechanisms drive aging resistance versus which reflect caloric reduction alone.
Stem cell therapy demonstrates potential to address frailty in aging by restoring cellular repair capacity and tissue regeneration. This approach targets a fundamental mechanism of aging decline rather than managing symptoms.
The Senotherapeutics Biomarker Consortium establishes standardized biomarkers for identifying and measuring cellular senescence across tissues and populations, enabling translation of senolytic therapies from research to clinical practice. This addresses a critical gap in longevity medicine: the ability to reliably detect senescent cells and track treatment response in living humans.
Caloric restriction reduces circulating C3a, a complement protein that drives inflammaging in aged tissues. This identifies a specific immunometabolic pathway through which moderate energy restriction extends healthspan in humans.
Gut microbiome composition predicts biological age and directly influences aging trajectories. Maintaining microbial diversity through dietary fiber and exercise represents a measurable pathway to extend healthspan, with fiber supplementation associated with 20–37% improvements in healthy aging outcomes.
Clinical evidence shows transplanted stem cells often fail to survive beyond days, yet patients continue improving—suggesting the therapeutic mechanism resides in transient molecular signals rather than cell persistence. This shift from cellular replacement to signal-based regenerative therapy reframes aging as a coordination failure rather than a structural deficit, with profound implications for scalable longevity medicine.
Fasting and caloric restriction activate ADIOL, a steroid hormone that signals through estrogen receptor β to reduce kynurenic acid in the nervous system and improve healthspan independent of lifespan extension. This mechanism appears evolutionarily conserved and remains effective even when ADIOL is supplemented late in life.
GlycanAge is hosting a conference with Mayo Clinic to advance clinical applications of glycan-based inflammaging markers, which can detect disease risk patterns up to a decade before symptomatic onset. The event aims to integrate chronic-inflammation testing into routine clinical practice.
Aging amplifies the liver's inflammatory and metabolic response to high-fat diet, increasing hepatic steatosis and transcriptional dysregulation. Rapamycin treatment reversed most diet-driven gene expression changes in older mice, reducing steatosis, body weight gain, and markers associated with liver disease progression.
Senotherapeutics—strategies that eliminate or reprogram senescent cells—represent a shift from broad-spectrum senolytic approaches toward precision interventions that target specific cell types and contexts. This progression directly addresses a fundamental mechanism of aging, offering potential to extend healthspan by restoring cellular function rather than relying solely on senescent cell elimination.
Single-nucleus RNA sequencing of vastus lateralis muscle from centenarians reveals a fundamental transcriptional reorganization characterized by a shift from metabolically robust fiber states to dysfunctional states accompanied by denervation and fatty infiltration. FAP-derived BMP and Laminin signaling emerges as a key driver of age-related muscle dysfunction, establishing specific molecular pathways amenable to therapeutic targeting.
Aging's complexity demands systems-level intervention rather than single-pathway targeting. The field is shifting from reductionist drug development toward multimodal approaches that account for how distinct physiological networks interact, compensate, and deteriorate over time.
Organ-specific aging clocks that integrate multiple molecular data types—genomics, epigenomics, transcriptomics, proteomics, and metabolomics—provide more accurate assessment of biological aging than single-measure approaches. This framework recognizes that individual organs age at different rates, offering a pathway to predict organ-specific disease risk and progression with greater precision.
The NUS Geromedicine Conference (February 2026) addresses the translation gap between geroscience mechanisms and clinical application, bringing together researchers, clinicians, and industry to move from pathway discovery to actionable protocols in real-world longevity practice.
